{
  "id": 5245603,
  "title": "Celltrion's Steqeyma Tops 16% U.S. Market Share",
  "url": "https://urgent.news/2026/09/03/celltrions-steqeyma-tops-16-u-s-market-share",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-03T04:42:29.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=276117"
  },
  "original_language": "en",
  "account": "In the US market for the autoimmune disease treatment ustekinumab, Celltrion's product Steqeyma has achieved a record 16% market share, according to IQVIA's latest figures. This market share figure has grown by 6% over the course of five months, rising from a 10.2% share in February to 16.2% in July. The success can be attributed to Celltrion's US subsidiary, which employs a localized sales strategy. Within a year of its launch, Steqeyma gained reimbursement coverage as a preferred drug on insurance formularies of major pharmacy benefit managers (PBMs) in the US. The strategy helped the product build its strong market position. The blood cancer treatment Truxima, a biosimilar, leads the market with a 38.6% market share, recording six consecutive months of top prescription ranking. Inflectra, a leading product in the infliximab market, maintains a 30.7% market share. Celltrion aims to boost sales by introducing follow-up products with high-profit margins, such as the chronic spontaneous urticaria treatment Omlyclo.",
  "summary": "In the US ustekinumab market, Celltrion’s autoimmune disease treatment ‘Steqeyma’ exceeded a 16% market share in about a year since its launch.According to the pharmaceutical market research firm IQVIA, Steqeyma recorded a 16.2% market share in the US market in July. This is a figure that has increa",
  "key_points": [
    "Celltrion's Steqeyma holds 16% U.S. market share in autoimmune disease treatment.",
    "Steqeyma's market share grew by 6% in five months, from 10.2% in February to 16.2% in July.",
    "Celltrion's localized sales strategy and insurance reimbursement contributed to Steqeyma's success."
  ],
  "editors_take": "Celltrion's localized US sales strategy and swift reimbursement coverage have enabled Steqeyma to rapidly gain market share in the ustekinumab treatment market, putting pressure on competing products.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}